In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Spiderman, but kind of goth: University of Bayreuth team creates red silk-producing spiders
In Germany, researchers at the University of Bayreuth’s Biomaterials research group have used the CRISPR-Cas9 gene-editing technology to create spiders that produce red fluorescent...
BoilMate corn-fiber cooking bowl seeks funding on Kickstarter
In California, Transcarton has launched a Kickstarter campaign for BoilMate—the world’s first fire-safe, compostable paper bowl engineered for instant cooking.
BoilMate combines FDA-approved corn fiber...
Natural Indigo Finland, TAMK turn coffee waste into ink for packaging
In Finland, Natural Indigo Finland and Tampere University of Applied Sciences (TAMK) have developed a water-based ink using biocolorant extracted from coffee waste supplied...